新型冠状病毒肺炎（COVID-19）合并糖尿病患者的药学服务和监护策略

新型冠状病毒肺炎（COVID-19）来势汹汹，而合并其他基础疾病的COVID-19患者更属于高危人群。血糖控制水平直接影响身体免疫应答和状态，其导致的免疫力低下状态极易增加患病几率，已感染的患者则更易加重感染，进一步继发细胞因子风暴。因此COVID-19合并2型糖尿病患者在疫情期间需要在治疗新型冠状病毒感染的同时做好血糖控制和管理。结合糖尿病合理用药相关研究，对COVID-19现有临床数据特征进行分析，探讨COVID-19合并糖尿病患者的药学实践模式和用药监护策略，以期对这类患者提供更为优化合理的用药方案，改善临床用药水平。

Pharmaceutical services and monitoring strategies for patients with new type of coronavirus pneumonia complicated by diabetes

New coronavirus pneumonia is menacing, and patients with new coronavirus pneumonia combined with other underlying diseases are more at risk. Glycemic control level directly affects the body''s immune response and body state. Its low immune status is extremely likely to increase the risk of illness. Infected patients are more likely to aggravate the infection and further cause cytokine storms. Therefore, patients with new type of coronavirus infection and type 2 diabetes need better blood glucose control and management while treating new type of coronavirus infection. This article combines the research on the rational use of diabetes and analyzes the characteristics of the existing clinical data of COVID-19 to explore the pharmacological practice mode and medication monitoring strategy of this special patient. It is hoped to provide COVID-19 patients with diabetes with a more optimized and reasonable medication regimen and improve the clinical medication level.